Immune Pharmaceuticals Inc. Stock Price - IMNPQ

Best deals to access real time data!
Small Cap Basic
Monthly Subscription
for only
$33.03
Ultimate Trader (Monthly)
Monthly Subscription
for only
$80.29
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
VAT not included
Company Name Stock Ticker Symbol Market Type
Immune Pharmaceuticals Inc. IMNPQ OTCMarkets Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  -0.000044 -1.64% 0.00264 0.0027 0.00235 0.00235 0.002684 11:10:47
Bid Price Ask Price Spread Spread % News
0.0025 0.0027 0.0002 7.41% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
10 223,187 $ 0.002605 $ 581 593,121 0.0012 - 0.02
Last Trade Time Type Quantity Stock Price Currency
11:10:47 20,000 $ 0.00264 USD

Immune Pharmaceuticals Inc. Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 427.45k 181.90M $ -17.89M - - 36.16M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
10.89k $ - 0.00% - -

more financials information »

Immune Pharmaceuticals Inc. News

Loading Messages....

Latest IMNPQ Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical IMNPQ Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.00230.0030.0020.0022694455,0210.0003414.78%
1 Month0.00450.00520.0020.0032416878,938-0.00186-41.33%
3 Months0.00830.00860.0020.0039501542,203-0.00566-68.19%
6 Months0.00460.00860.0020.0047011459,296-0.00196-42.61%
1 Year0.01850.020.00120.00581772,299,994-0.01586-85.73%
3 Years0.160.170.00120.01090161,833,559-0.15736-98.35%
5 Years0.160.170.00120.01090161,833,559-0.15736-98.35%

Immune Pharmaceuticals Inc. Description

Immune Pharmaceuticals Inc., together with its subsidiaries (collectively, "Immune" or the "Company" or "us," "we," or "our") is a clinical stage biopharmaceutical company specializing in the development of novel targeted therapeutic agents in the fields of inflammation, dermatology and oncology. Our lead product candidate is bertilimumab, a first-in-class, human, anti-eotaxin-1 antibody that targets eotaxin-1, a key regulator of inflammation. Phase 2 trials of bertilimumab in bullous pemphigoid ("BP"), our lead indication, as well as in allergic rhinitis and allergic conjunctivitis, have been completed, and a phase 2 clinical trial in ulcerative colitis ("UC") has completed recruiting subjects, although this trial remains blinded. We are also developing a nano-encapsulated topical formulation of cyclosporine-A, which we refer to as "NanoCyclo," for the treatment of atopic dermatitis ("AD") and psoriasis. We also own certain rights to Ceplene, which is approved in the European Union for the maintenance of remission in patients with Acute Myeloid Leukemia ("AML") in combination with interleukin-2 (IL-2).


Your Recent History
USOTC
IMNPQ
Immune Pha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.